NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTREXA VISCOUS IN DEXTRAN 20% is a riboflavin 5-phosphate ophthalmic solution administered as eye drops for corneal cross-linking procedures. It is used in conjunction with UVA light exposure to strengthen corneal collagen and halt progressive keratoconus. The mechanism involves riboflavin acting as a photosensitizer that generates reactive oxygen species upon UV activation, cross-linking corneal collagen fibers.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), indicating stable demand but potential team consolidation as market matures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PHOTREXA VISCOUS offers career opportunities in a specialized, high-margin ophthalmology segment with direct access to proceduralists and surgical centers. The niche market and peak lifecycle stage indicate stable but not rapidly expanding team sizes, favoring deep expertise-building over rapid advancement.
Regional Sales Manager (Ophthalmology)Medical Science Liaison (Corneal/Refractive Surgery)
Worked on PHOTREXA VISCOUS IN DEXTRAN 20% at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.